RU2736509C2 - [9,10-диметокси-3-(2-метилпропил)-1h,2h,3h,4h,6h,7h,11bh- пиридо-[2,1-a]изохинолин-2-ил]метанол и связанные с ним соединения, композиции и способы - Google Patents

[9,10-диметокси-3-(2-метилпропил)-1h,2h,3h,4h,6h,7h,11bh- пиридо-[2,1-a]изохинолин-2-ил]метанол и связанные с ним соединения, композиции и способы Download PDF

Info

Publication number
RU2736509C2
RU2736509C2 RU2017130514A RU2017130514A RU2736509C2 RU 2736509 C2 RU2736509 C2 RU 2736509C2 RU 2017130514 A RU2017130514 A RU 2017130514A RU 2017130514 A RU2017130514 A RU 2017130514A RU 2736509 C2 RU2736509 C2 RU 2736509C2
Authority
RU
Russia
Prior art keywords
alkyl
pyrido
dimethoxy
methylpropyl
optionally substituted
Prior art date
Application number
RU2017130514A
Other languages
English (en)
Russian (ru)
Other versions
RU2017130514A3 (https=
RU2017130514A (ru
Inventor
Нейл Эшвик
Николь ХАРРИОТТ
Original Assignee
Ньюрокрайн Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ньюрокрайн Байосайенсиз, Инк. filed Critical Ньюрокрайн Байосайенсиз, Инк.
Publication of RU2017130514A publication Critical patent/RU2017130514A/ru
Publication of RU2017130514A3 publication Critical patent/RU2017130514A3/ru
Application granted granted Critical
Publication of RU2736509C2 publication Critical patent/RU2736509C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2017130514A 2015-02-06 2016-02-05 [9,10-диметокси-3-(2-метилпропил)-1h,2h,3h,4h,6h,7h,11bh- пиридо-[2,1-a]изохинолин-2-ил]метанол и связанные с ним соединения, композиции и способы RU2736509C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113316P 2015-02-06 2015-02-06
US62/113,316 2015-02-06
PCT/US2016/016892 WO2016127133A1 (en) 2015-02-06 2016-02-05 [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

Publications (3)

Publication Number Publication Date
RU2017130514A RU2017130514A (ru) 2019-03-07
RU2017130514A3 RU2017130514A3 (https=) 2019-08-27
RU2736509C2 true RU2736509C2 (ru) 2020-11-17

Family

ID=55404854

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017130514A RU2736509C2 (ru) 2015-02-06 2016-02-05 [9,10-диметокси-3-(2-метилпропил)-1h,2h,3h,4h,6h,7h,11bh- пиридо-[2,1-a]изохинолин-2-ил]метанол и связанные с ним соединения, композиции и способы

Country Status (12)

Country Link
US (4) US9714246B2 (https=)
EP (1) EP3253752B1 (https=)
JP (1) JP6755254B2 (https=)
KR (1) KR102586138B1 (https=)
CN (1) CN107438606B (https=)
AU (1) AU2016215033B2 (https=)
CA (1) CA2974540C (https=)
ES (1) ES2960717T3 (https=)
IL (1) IL253704B (https=)
MX (1) MX375718B (https=)
RU (1) RU2736509C2 (https=)
WO (1) WO2016127133A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112642A1 (en) 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
CA2974540C (en) 2015-02-06 2023-09-26 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
MY193767A (en) 2015-10-30 2022-10-27 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
ES3024958T3 (en) 2017-09-21 2025-06-05 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
CA3121920A1 (en) 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
PT4168409T (pt) 2021-03-22 2025-06-12 Neurocrine Biosciences Inc Inibidores de vmat2 e métodos de utilização
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
RU2339636C2 (ru) * 2003-06-20 2008-11-27 Ф.Хоффманн-Ля Рош Аг Гексагидропиридоизохинолины в качестве ингибиторов дипептидилпептидазы iv (dpp-iv)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54125699A (en) 1978-03-17 1979-09-29 Nippon Chemiphar Co Ltd Preparation of ( ) dihydroprotoemetine
RU2339363C2 (ru) 2006-12-28 2008-11-27 Лидия Ибрагимовна Гайсанова Мазь "бунхо", обладающая противовоспалительным и регенерирующим действием
NZ760790A (en) * 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
CA2974540C (en) 2015-02-06 2023-09-26 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2339636C2 (ru) * 2003-06-20 2008-11-27 Ф.Хоффманн-Ля Рош Аг Гексагидропиридоизохинолины в качестве ингибиторов дипептидилпептидазы iv (dpp-iv)
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUNG H. F. et al., In vivo imaging of vesicular monoamine transporter 2 in pancreas using an <18>F epoxide derivative of tetrabenazine, NUCLEAR MEDICINE AND BIOIGY, 2008, vol. 35, p. 825-837. ARANDA G. et al., Synthesis and biological activity of iodinated and photosensitive derivatives or tetrabenazine, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1990, vol. 25, p. 369-374. KILBOURN M. R. et al., Absolute Configuration of(+)-a-Dihydrotetrabenazine, an Active Metaboliteof Tetrabenazine, CHIRALITY, 1997, vol.9, p. 59-62. *

Also Published As

Publication number Publication date
MX2017010062A (es) 2017-11-01
MX375718B (es) 2025-03-06
ES2960717T3 (es) 2024-03-06
CN107438606A (zh) 2017-12-05
CA2974540C (en) 2023-09-26
US20200262834A1 (en) 2020-08-20
BR112017016934A2 (pt) 2018-04-03
US11053242B2 (en) 2021-07-06
IL253704A0 (en) 2017-09-28
US20170349586A1 (en) 2017-12-07
RU2017130514A3 (https=) 2019-08-27
CN107438606B (zh) 2020-09-18
AU2016215033A1 (en) 2017-08-10
RU2017130514A (ru) 2019-03-07
EP3253752C0 (en) 2023-08-16
NZ733899A (en) 2024-01-26
JP2018504437A (ja) 2018-02-15
US20160289226A1 (en) 2016-10-06
WO2016127133A1 (en) 2016-08-11
US9714246B2 (en) 2017-07-25
JP6755254B2 (ja) 2020-09-16
KR102586138B1 (ko) 2023-10-05
US9988382B2 (en) 2018-06-05
CA2974540A1 (en) 2016-08-11
EP3253752A1 (en) 2017-12-13
EP3253752B1 (en) 2023-08-16
IL253704B (en) 2021-02-28
AU2016215033B2 (en) 2020-06-25
KR20170113620A (ko) 2017-10-12
US20180273533A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
RU2736509C2 (ru) [9,10-диметокси-3-(2-метилпропил)-1h,2h,3h,4h,6h,7h,11bh- пиридо-[2,1-a]изохинолин-2-ил]метанол и связанные с ним соединения, композиции и способы
US11098031B1 (en) Inhibitors of RAF kinases
US9975890B2 (en) Bicyclic AZA compounds as muscarinic M1 receptor antagonists
CA2948161C (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
KR20180073685A (ko) 신경계 질환을 치료하기 위한, 무스카린성 수용체 4 (m4) 길항제로서의 n-[2-(1-벤질피페리딘-4-일)에틸]-4-(피라진-2-일)-피페라진-1-카르복스아미드 유도체 및 관련된 화합물
AU2016231951A1 (en) Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptor
US9708302B2 (en) Flouro-naphthyl derivatives
KR20100082349A (ko) 치환된 ｎ－페닐-비피롤리딘 우레아 및 이의 치료적 용도
US10781202B2 (en) Azetidinyloxyphenylpyrrolidine compounds
US8093237B2 (en) Dibenzo[b,f][1,4]oxazapine compounds
FI113769B (fi) Neurosuojaavia kromaaniyhdisteitä
KR20240115832A (ko) 헌팅턴병을 치료하기 위한 htt 조절제
US20240059677A1 (en) Substituted pyrimidine derivatives as nicotinic acetylcholinesterase receptor alpha 6 modulator
TW202502752A (zh) 嘧啶化合物及其作為usp1抑制劑的用途
CN118302423A (zh) 胺类化合物及其用途
BR112017016934B1 (pt) Compostos inibidores do transportador vesicular de monoamina 2 (vmat2), composição farmacêutica compreendendo os mesmos, uso dos mesmos para tratar um transtorno hipercinético, esquizofrenia e transtorno bipolar e método para preparar a dita composição farmacêutica

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant